Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¸¸¼º°ñ¹ÝÅëÁõÈıº ȯÀÚÀÇ Ä¡·á¿¡¼­ Terpene Mixture¿Í ¾ËÆÄÂ÷´ÜÁ¦ÀÇ Ä¡·áÈ¿°ú ºñ±³: ÀüÇâÀû ¿¬±¸ Comparison of the Efficacy of a Terpene Mixture and Alpha-Blocker for Treatment of Category III Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Prospective Study

´ëÇѺñ´¢±â°úÇÐȸÁö 2009³â 50±Ç 2È£ p.148 ~ 153
Â÷¿ìÇå, ±è±âÈ£, ¼­¿µÁø,
¼Ò¼Ó »ó¼¼Á¤º¸
Â÷¿ìÇå ( Cha Woo-Heon ) 
µ¿±¹´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

±è±âÈ£ ( Kim Ki-Ho ) 
µ¿±¹´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç
¼­¿µÁø ( Seo Young-Jin ) 
µ¿±¹´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

Abstract


Purpose: The aim of this study was to evaluate the efficacy of a terpene mixture compared with alpha-blocker in patients with chronic pelvic pain syndrome (CPPS).

Materials and Methods: Patients diagnosed with CPPS were included in this study. The patients were randomly placed into three groups. Group 1 was treated with levofloxacin alone (36 patients), group 2 was treated with levofloxacin and alfuzosin (33 patients), and group 3 was treated with levofloxacin and terpene mixture (34 patients) for 8 weeks. The National Institutes of Health Chronic Prostatitis Symptom Index (NIH- CPSI) was evaluated in patients in each group at the beginning of the study and after 8 weeks of treatment.

Results: Pain domain, urinary domain, quality of life domain, and total score on the NIH-CPSI were not significantly different at the initial visit. After treatment with each medication, improvements on the pain domain and total score of the NIH-CPSI were better in group 3 than in group 1 or group 2 (p£¼0.05). Improvement on the urinary domain of the NIH-CPSI was better in group 2 than in group 1 or group 3 (p=0.014). Changes in the quality of life domain of the NIH-CPSI were not significant among the three groups.

Conclusions: This study suggests that the terpene mixture and alpha- blockers may have significant benefit for symptomatic relief, especially in the pain and urinary domains, respectively.

Å°¿öµå

Pelvic pain;Adrenergic alpha-antagonists;Terpenes

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS